Table 2 Radiation dose rate, elapsed time, and cumulative dose due to staff exposure to thyroid cancer patients treated with RAI-131 for the Group-A
Phase | Range, Average Dose rate (μSv/h) | Elapsed time, (min) | Average accumulative dose, (μSv) | Dose reduction factor (FR) | Γ,( μSv m2/MBq h) |
|---|---|---|---|---|---|
2 h | (67.0–91.1) | 1.3 ± 0.2 | 1.70 ± 0.57 | 0.999 | 0.021 ± 0.004 |
79.1 ± 12.1 | |||||
Second day | (14.6–31.0) | 1.5 ± 0.3 | 0.70 ± 0.23 | 0.998 | 0.006 ± 0.002 |
22.7 ± 8.5 | |||||
Third day | (5.0–9.2) | 2.0 ± 0.1 | 0.20 ± 0.12 | 0.997 | 0.002 ± 0.001 |
7.0 ± 4.0 | |||||
Fourth day | (1.6–4.2) | 2.2 ± 0.5 | 0.10 ± 0.10 | 0.995 | 0.001 ± 0.001 |
2.9 ± 1.3 | |||||
Fifth day | (1.0–2.8) | ||||
1.9 ± 0.9 | 2.5 ± 0.9 | 0.08 ± 0.08 | 0.993 | 0.00 ± 0.001 |